Emergency management of atrial fibrillation

A Wakai, J O O'Neill

Atrial fibrillation is the most common cardiac arrhythmia managed by emergency and acute general physicians. There is increasing evidence that selected patients with acute atrial fibrillation can be safely managed in the emergency department without the need for hospital admission. Meanwhile, there is significant variation in the current emergency management of acute atrial fibrillation. This review discusses evidence based emergency management of atrial fibrillation. The principles of emergency management of acute atrial fibrillation and the subset of patients who may not need hospital admission are reviewed. Finally, the need for evidence based guidelines before emergency department based clinical pathways for the management of acute atrial fibrillation becomes routine clinical practice is highlighted.

Atrial fibrillation is a supraventricular tachyarrhythmia characterised electrocardiographically by replacement of consistent P waves by rapid, irregular, fibrillatory waves that vary in size, shape, and timing. It is associated with an irregular, frequently rapid, ventricular response when atrioventricular node conduction is intact.

Atrial fibrillation affects up to 4% of those over 60 years of age and may be an independent risk factor for death. After adjustment for known risk factors, the relative risk of mortality is 1.5 for men and 1.9 for women. Atrial fibrillation is rare in the first two decades of life, but when it does occur is usually associated with congenital heart disease or an accessory pathway.

The mechanism of initiation of atrial fibrillation is likely to be multifactorial and might be related to the tachycardia cycle length, intrinsic atrial vulnerability, contraction-excitation feedback, or a combination of these factors. Atrial fibrillation is frequently precipitated by underlying cardiac (hypertensive heart disease, heart failure, acute myocardial infarction, pericarditis, myocarditis, cardiac surgery) or non-cardiac disease (hyperthyroidism, pulmonary embolism, pneumonia, chronic obstructive pulmonary disease). Probably through atrial remodelling (frequently inflammation or fibrosis), conditions which precipitate atrial fibrillation act as a substrate for further development of atrial fibrillation.

Atrial fibrillation is the most common sustained cardiac arrhythmia, accounting for approximately 35% of hospital admissions for cardiac arrhythmias. Hence, it is the most common form of cardiac arrhythmia emergency physicians manage. Meanwhile, its prevalence is increasing along with the aging population in the Western world.

With the advent of clinical decision units, and as more prolonged periods of management become common in the emergency department, the need to admit all patients with acute atrial fibrillation has been questioned. There is increasing evidence that selected patients with acute atrial fibrillation can be safely managed in an emergency department observation unit or clinical decision unit without the need for hospital admission. In one study, a third of patients with new onset atrial fibrillation did not require hospital admission. Furthermore, an emergency department based clinical pathway for the management of acute atrial fibrillation is associated with substantial reduction in hospital length of stay and a favourable trend of cost savings. Meanwhile, a recent survey of accident and emergency consultants in the United Kingdom revealed a wide variation in management practices of atrial fibrillation, especially with regard to cardioversion and anticoagulation therapy. It highlighted the need for evidence based guidelines for acute atrial fibrillation management in the emergency department setting.

CLASSIFICATION OF ATRIAL FIBRILLATION

Although there is no universal consensus on the nomenclature or classification of atrial fibrillation, a simple and clinically relevant classification has been proposed by the American College of Cardiology/American Heart Association/European Society of Cardiology practice guidelines for the management of atrial fibrillation. In this classification, paroxysmal atrial fibrillation is self terminating; persistent atrial fibrillation is not self terminating and requires treatment for termination; in permanent atrial fibrillation, sinus rhythm cannot be sustained after cardioversion of atrial fibrillation or the patient and physician have decided to allow atrial fibrillation to continue without further efforts to restore sinus rhythm. New onset atrial fibrillation may present in the emergency department setting as paroxysmal or persistent atrial fibrillation (fig 1). In this setting, patients presenting with symptomatic acute atrial fibrillation may have new onset
atrial fibrillation (fig 1), recurrent paroxysmal (fig 2), or recurrent persistent atrial fibrillation (fig 3). Permanent atrial fibrillation is more likely to be an incidental finding in the emergency department setting.

The term “lone atrial fibrillation” describes atrial fibrillation in the absence of demonstrable underlying cardiac disease (coronary artery disease, heart failure, valvular heart disease, cardiomyopathy) or a history of hypertension. It occurs in approximately 3%–35% of patients with atrial fibrillation, depending on the population studied. Lone atrial fibrillation may be due to pulmonary vein ectopic foci, proarrhythmic atrial fibrotic areas, increased susceptibility to autonomic neural stimuli to the heart, circulating autoantibodies against cardiac myosin heavy chains, or, very rarely, localised atrial myocarditis. In patients 60 years and younger, lone atrial fibrillation, although uncommon, has a very small risk of thromboembolism which does not justify warfarin therapy. In contrast, in patients 60 years or older with lone atrial fibrillation warfarin therapy is justified because of an increased risk of stroke and death.

Patients with the Wolff-Parkinson-White syndrome presenting with acute atrial fibrillation represent a distinct entity, because special precautions are required in their emergency management. In this condition, there is prolonged atrial conduction and greater atrial vulnerability to development of atrial fibrillation. Rapid atrioventricular conduction over the accessory conduction pathway may precipitate fatal ventricular fibrillation. In the presence of Wolff-Parkinson-White syndrome, drugs that slow atrial fibrillation by blocking conduction through the atrioventricular node (digoxin, β-blockers, and calcium channel blockers) are contraindicated because they do not slow conduction over the accessory pathways and may therefore precipitate ventricular fibrillation.

WHAT ARE THE PRINCIPLES OF EMERGENCY MANAGEMENT OF ATRIAL FIBRILLATION?

In all patients presenting to the emergency department with acute atrial fibrillation, immediate provision of supplementary oxygen, establishment of an intravenous line, and continuous electrocardiographic monitoring is mandatory. In the emergency department assessment of atrial fibrillation (box 1),
attention should also be paid to the need for alcohol withdrawal prophylaxis in patients with alcohol induced atrial fibrillation ("holiday heart syndrome") and alcohol induced liver disease.

The principles of emergency management of atrial fibrillation are prevention of thromboembolism, haemodynamic stabilisation, and symptom relief. These goals are achieved by a three part approach to management.

Firstly, to prevent the risk of embolic stroke associated with restoration of sinus rhythm (cardioversion), anticoagulation is required (figs 1–3). Although the risk of thromboembolism is low (0.8%) if atrial fibrillation is of <48 hours’ duration, emergency department patients should not be assumed to be free of left atrial thrombus because 15% of patients with acute atrial fibrillation (that is, <3 days) have evidence of atrial thrombi. Transoesophageal echocardiography (TOE) before cardioversion, to rule out occult left atrial appendage thrombi, is not presently available in the emergency department setting. Current guidelines state that in patients with atrial fibrillation undergoing cardioversion, anticoagulation therapy should be administered regardless of the method (chemical or electrical) used to restore sinus rhythm.

Secondly, ventricular rate should be appropriately controlled. This is of primary importance in stable acute atrial fibrillation patients with rapid ventricular rate (figs 1–3). Allowing the persistence of atrial fibrillation but controlling the ventricular response has the advantage of avoiding the potential proarrhythmic side effects of antiarrhythmic drugs. The rate is generally considered controlled when the ventricular response ranges between 60 and 80 beats/min at rest.

Thirdly, the need for, the proper timing of, and the appropriate method of cardioversion should be assessed. Cardioversion, theoretically, relieves symptoms, prevents thromboembolism, and prevents cardiomyopathy of tachycardia (tachycardiomyopathy). It also improves cardiac output and exercise capacity, particularly in patients with heart failure.

In symptomatic patients already taking warfarin, emergency management of acute atrial fibrillation depends on the international normalised ratio (INR). If it can be confirmed, from medical records, that the INR has been recently therapeutic (generally >2.0) for three or more weeks immediately cardioversion is indicated in haemodynamically unstable patients. However, since ventricular rate control can now be considered a primary management strategy in acute atrial fibrillation, it is more appropriate if the patient is haemodynamically stable and the INR is subtherapeutic or unknown.

VENTRICULAR RATE CONTROL OR CARDIOVERSION IN ACUTE ATRIAL FIBRILLATION?

Two different strategies exist for the emergency management of cardiac rhythm in patients with acute atrial fibrillation. The first entails allowing atrial fibrillation to persist while ventricular rate is controlled. The second is cardioversion and attempting to maintain sinus rhythm with antiarrhythmic drugs. Until recently ventricular rate control was intuitively considered somewhat inferior to cardioversion, because persistence of atrial fibrillation was thought to lead to
The choice of chemical or electrical cardioversion depends on the patient. For example, in patients with hypertension electrical cardioversion may be thrombogenic. Thus, in these patients, chemical cardioversion may be the method of choice for restoration of sinus rhythm. Available facilities and expertise (physician experience) in the emergency department also determines which method of cardioversion can be used. For example, it is desirable to have facilities with emergency external cardiac pacing available whenever electrical cardioversion is attempted because sinus asytole may occur after cardioversion.

Compared with electrical cardioversion, chemical cardioversion is simpler but less efficacious, being successful in approximately 50% of emergency department patients. However, no sedation or anaesthesia backup is required for successful chemical conversion. Emergency department electrical cardioversion is successful in approximately 80% to 89% of cases but requires intravenous sedation. In this regard, short acting intravenous anaesthetic agents producing conscious sedation are preferable because rapid recovery post-cardioversion may avoid hospital admission. Patients who undergo a failed attempt at chemical cardioversion can subsequently undergo successful electrical cardioversion.

Immediate electrical cardioversion is recommended in patients with acute atrial fibrillation and a rapid ventricular response associated with acute myocardial infarction, symptomatic hypertension, angina, or heart failure that does not respond promptly to pharmacological measures.

WHAT IS THE BEST PHARMACOLOGICAL AGENT FOR EMERGENCY VENTRICULAR RATE CONTROL?

Ventricular rate control is achieved by depression of atrioventricular nodal conduction. Agents which may be administered to achieve emergency rate control include β-blockers (metoprolol, propranolol, esmolol), calcium channel blockers (verapamil, diltiazem), digoxin, or amiodarone.

These drugs depress atrioventricular nodal conduction by a variety of different mechanisms. Calcium channel blockers such as verapamil and diltiazem target the L-type calcium channel. Beta-blockers prolong atrioventricular refractoriness by targeting the β-adrenergic receptors. The predominant effect of digoxin on the atrioventricular node is mediated by enhanced vagal tone. Meanwhile, amiodarone has both sympatholytic and calcium antagonistic properties.

The selection of a β-blocker or calcium channel blocker should be based on the physician’s experience and the patient’s clinical condition. For example, a β-blocker is preferable in patients with acute myocardial infarction or ischaemic heart disease but contraindicated in asthmatics. Although a direct comparison of rate control effect using different β-blockers has not been performed, theoretically, esmolol (an ultrashort acting β-blocker administered intravenously) may be the best β-blocker in the emergency department setting. It has the advantage in the emergency department setting of easy titration, due to its short plasma half life (nine minutes). Its main drawback is that it is cumbersome to use because multiple doses and multiple infusion steps are required.

Verapamil and diltiazem are the calcium channel blockers commonly used for rate control in acute atrial fibrillation. Intravenously, each drug is effective in the emergency setting, but the response is transient, and repeated doses or a continuous intravenous infusion may be required to maintain heart rate control. Calcium channel blockers, particularly verapamil, are contraindicated in patients with heart failure.

In acute atrial fibrillation patients with Wolff-Parkinson-White syndrome calcium channel blockers and β-blockers are contraindicated for rate control because anterograde conduction along the accessory pathway is facilitated when these agents are administered. This may result in markedly
increased ventricular rate, hypotension, and degeneration into ventricular fibrillation. In haemodynamically stable patients with Wolff-Parkinson-White syndrome, type I (for example, quinidine, procainamide, disopyramide) or type III (for example, ibutilide or amiodarone) antiarrhythmic agents may be used. However, a combination of drugs, with careful dose titration, may be necessary to control the rate of ventricular response in patients with acute atrial fibrillation.

**WHAT IS THE BEST PHARMACOLOGICAL AGENT FOR EMERGENCY CARDIOVERSION?**

In acute atrial fibrillation, several drugs are effective in restoring sinus rhythm. These include ibutilide, propafenone, flecaïnide, and sotalol. These agents increase the length of the interval between paroxysms but often do not totally abolish the arrhythmia. The treatment of acute atrial fibrillation with antiarrhythmic drugs that also slow the heart rate (such as sotalol) may simply convert symptomatic episodes to asymptomatic ones.

The success rate of individual drugs is highly variable from different studies because of differences in patient selection and definitions of successful cardioversion. Nevertheless, existing data suggest ibutilide is probably the most effective agent for the chemical cardioversion of acute atrial fibrillation in the emergency department setting. Ibutilide has a rapid action (within one hour after administration) and is safe in patients with Wolff-Parkinson-White syndrome. Its main drawback is induction of torsades de pointes (TDP), with an incidence of 3.6% to 8.3%. Electrocardiographic monitoring is, therefore, mandatory when using intravenous ibutilide. Patients should be monitored for at least four hours after initiation of ibutilide therapy. In contrast to other antiarrhythmic drug induced TDP (which usually occurs after successful cardioversion), ibutilide induced TDP may occur before conversion to sinus rhythm. Because of its rapid action, ibutilide induced TDP is usually transient (one to two hours) and no intervention is required in haemodynamically stable patients.

**WHAT IS THE ROLE OF DIGOXIN IN THE EMERGENCY MANAGEMENT OF ATRIAL FIBRILLATION?**

Although digitalis compounds have been used to treat atrial fibrillation for over two centuries, more recent studies have shown that in some patients with atrial fibrillation, digoxin has little or no effect in terminating the arrhythmia, and may occasionally be detrimental. It may aggravate paroxysmal atrial fibrillation by shortening the atrial muscle refractory period and increasing the rate of fibrillation. In new onset atrial fibrillation, digoxin is not effective in restoring sinus rhythm. Although digoxin may effectively slow the ventricular rate, there is a delay of at least 60 minutes before onset of a therapeutic effect in most patients, and peak systemic levels do not develop for up to six hours. Controlled studies have demonstrated that the conversion rate to sinus rhythm by digoxin is no better than placebo, although the effect of digoxin in slowing the ventricular response during atrial fibrillation is unquestioned. When digoxin is used alone, there is a tendency for a relapse into unstable heart rates after initial rate control. Despite these limitations, digoxin is still considered by many emergency physicians as a first line agent for emergency department rate control in acute atrial fibrillation. Furthermore, many emergency physicians would administer digoxin intravenously, although there is little pharmacological advantage over the oral route, except in patients in whom it cannot be administered enterally.

Because the predominant effect of digoxin on the atrioventricular node is mediated by enhanced vagal tone, it is useful for controlling the resting ventricular rate in atrial fibrillation, but ineffective for rate control in conditions of high sympathetic drive, including pyrexia or severe heart failure. In these situations, calcium channel blockers and β-blockers are more effective for rapid rate control in the emergency department setting.

The advantage of digoxin is its mild positive inotropic effect. It is, therefore, recommended that digoxin should mainly be used as a second line agent or reserved for those with heart failure or left ventricular dysfunction.

**IS EMERGENCY DEPARTMENT INITIATION OF ANTIARRHYTHMIC PROPHYLAXIS FEASIBLE?**

After successful cardioversion, it is necessary to start the patient on an antiarrhythmic drug to prevent atrial fibrillation recurrence, if the patient has no identifiable reversible causes (figs 1–3). Drugs of choice to prevent recurrent atrial fibrillation and maintain normal sinus rhythm include class I (for example, procainamide) or class III (for example, sotalol and amiodarone) antiarrhythmic agents. Intravenous procainamide infusion (2–5 mg/min) is usually effective in preventing immediate recurrence of atrial fibrillation in the emergency department setting. More recently, "pure" class III agents such as dofetilide, a highly selective potassium channel blocker, have also been shown to effectively prevent recurrence of atrial fibrillation after cardioversion.

Whether oral antiarrhythmic drug treatment should be initiated on an inpatient or outpatient basis is an ongoing debate. The decision depends on the patient symptoms, the presence of structural heart disease, and the type of drug. For example, initiation of sotalol or quinidine requires hospital admission because of the risk of TDP with these drugs. Outpatient initiation of antiarrhythmic treatment is feasible for individuals who are asymptomatic, have normal QT intervals on an electrocardiogram, and no significant heart disease.

Patients started on amiodarone may be safe for discharge after emergency cardioversion because of its minimal depression of myocardial function and low proarrhythmia potential. Amiodarone is currently the only agent for which there are substantial data to support initiation of outpatient treatment for atrial fibrillation.

**WHICH SUBSET OF ATRIAL FIBRILLATION PATIENTS NEED HOSPITAL ADMISSION?**

Currently, a common practice in patients with acute atrial fibrillation is admission for rate control, anticoagulation, exclusion of myocardial infarction and other causes of atrial fibrillation, and possible cardioversion to restore sinus rhythm. This strategy usually incorporates a TOE guided strategy with cardioversion on intravenous heparin (if the TOE is negative for atrial thrombi) and subsequent anticoagulation with warfarin. Alternatively, patients are admitted for rate control and anticoagulation with subsequent outpatient elective cardioversion after therapeutic warfarin anticoagulation for three consecutive weeks.

Hospitalisation can be limited to highly symptomatic patients, those with structural heart disease, those who have had an embolic event or are at high risk of thromboembolism (such as patients with rheumatic mitral valve disease), and patients with failure of rate control in the emergency department.

Inpatient electrocardiographic monitoring may also be required for those patients who, although successfully cardioverted in the emergency department, are started on oral antiarrhythmic therapy with high proarrhythmia potential (for example, sotalol and quinidine).
Patients with non-cardiac causes of atrial fibrillation may also require hospital admission for appropriate management. For example, when acute atrial fibrillation is associated with acute exacerbation of chronic obstructive pulmonary disease, management of the underlying lung disease with correction of hypoxia and acid balance are of primary importance.

WHICH SUBSET OF ATRIAL FIBRILLATION PATIENTS CAN BE SAFELY DISCHARGED FROM THE EMERGENCY DEPARTMENT?

Broadly speaking, two categories of patients may be safely discharged from the emergency department: those with no structural heart disease and those who have a controlled ventricular rate. Patients younger than 60 years old with lone atrial fibrillation have a benign prognosis and may also not need hospital admission. Hospital admission is not necessary solely to rule out myocardial infarction in patients with new onset atrial fibrillation, in the absence of angina, electrocardiographic evidence of myocardial ischaemia, or a recent infarction. Ischaemic heart disease rarely presents as atrial fibrillation in the absence of other signs or symptoms, except in elderly or diabetic patients.

Patients with persistent atrial fibrillation whose rhythm is converted to normal sinus rhythm by emergency department cardioversion can be discharged home after initiation of an appropriate oral antiarrhythmic treatment to prevent recurrence (fig 1). In patients with acute atrial fibrillation, especially if symptoms related to arrhythmia are minimal, acceptance of rate controlled atrial fibrillation is an option (figs 1–3). In a recent study, 4% of patients with acute atrial fibrillation managed in the emergency department were discharged home in rate controlled atrial fibrillation with no complications on follow up. All patients discharged home should be closely monitored, and both the patient and the physician should be alert to possible adverse drug effects.

CONCLUSIONS

Spontaneous conversion to sinus rhythm occurs within 24 hours after onset of acute atrial fibrillation in up to two thirds of patients. In haemodynamically stable patients, for the moment, the default position when faced with a patient with acute atrial fibrillation must be to manage them conservatively with rate control rather than attempt cardioversion. In haemodynamically unstable patients, immediate electrical cardioversion is indicated.

Not all patients with acute atrial fibrillation presenting to an emergency department need hospital admission. It is feasible to safely manage and discharge a subset of patients with acute atrial fibrillation in an emergency department observation unit or clinical decision unit. Management should be individualised to each patient depending on several factors including patient symptoms, known duration of atrial fibrillation, and the presence of structural heart disease. Evidence based guidelines are required for safe and uniform emergency department management of acute atrial fibrillation due to the current wide variation in management practices and unnecessary hospital admission of some patients with acute atrial fibrillation.

CONTRIBUTORS

Abel Wakai initiated the review, searched the emergency medicine literature for relevant papers, and prepared the first draft of the manuscript. James O O’Neill searched the cardiology literature for relevant papers and appraised the manuscript for conformity to cardiology practice. Abel Wakai and James O O’Neill produced the final manuscript. Abel Wakai acts as the guarantor for the paper.

Authors’ affiliations

A Wakai, Department of Emergency Medicine, Beaumont Hospital, Dublin, Republic of Ireland

J O O’Neill, Department of Medicine, Our Lady’s Hospital, Navan, Republic of Ireland

REFERENCES


